Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer
Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer
复制标题
DOI：
10.1097/sla.0000000000003049
复制
发表时间：
2020-04-01
影响因子：
9
通讯作者：
Evans, Douglas B.
中科院分区：
文献类型：
--
作者：
Tsai, Susan;George, Ben;Evans, Douglas B.
目的：碳水化合物抗原19-9（CA 19 -9）是胰腺癌（PC）患者的预后标志物，但其作为治疗生物标志物的价值尚不清楚。背景数据摘要：尽管CA 19 -9是PC患者的既定预后标志物，但尚不清楚如何使用CA 19 -9监测来指导多模式治疗，以及CA 19 -9的变化水平构成有意义的治疗反应。研究方法：在诊断时CA 19 -9升高（>= 35 U/dL）的局限性PC患者中，分析了诊断时（pretx）、完成所有计划的新辅助治疗后（术前）和手术后（术后）的CA 19 -9测量值。患者按以下分类：1）pretx CA 19 -9的四分位数（Q1-4）; 2）新辅助治疗完成后CA 19 -9的比例变化（Delta CA 19 -9）; 3）正常化（CA 19 -9
Objective: Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary Background Data: Although CA19-9 is an established prognostic marker for patients with PC, it is unclear how CA19-9 monitoring should be used to guide multimodality treatment and what level of change in CA19-9 constitutes a meaningful treatment response. Methods: CA19-9 measurements at diagnosis (pretx), after completion of all planned neoadjuvant therapy (preop), and after surgery (postop) were analyzed in patients with localized PC who had an elevated CA19-9 (>= 35 U/dL) at diagnosis. Patients were classified by: 1) quartiles of pretx CA19-9 (Q1-4); 2) proportional changes in CA19-9 (Delta CA19-9) after the completion of neoadjuvant therapy; 3) normalization (CA19-9